Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 22 of 22 matching drugs for HDAC8 — including drugs targeting any of its 13 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC8 Direct 2
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat HDAC8 Direct 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat HDAC8 Direct 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab HDAC8 Direct 1
bevacizumab, temozolomide, vorinostat HDAC8 Direct 1
capecitabine, vorinostat, radiotherapy, surgery to remove tumor HDAC8 Direct 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff HDAC8 Direct 1
laboratory biomarker analysis, pharmacological study, temozolomide, vorinostat HDAC8 Direct 1
pembrolizumab, vorinostat, temozolomide, radiotherapy HDAC8 Direct 1
vorinostat, bevacizumab HDAC8 Direct 1
vorinostat, bevacizumab, irinotecan HDAC8 Direct 1
vorinostat, bortezomib, pharmacological study, laboratory biomarker analysis HDAC8 Direct 1
vorinostat, conventional surgery HDAC8 Direct 1
vorinostat, temozolomide, diagnostic laboratory biomarker analysis, pharmacological study HDAC8 Direct 1
vorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administration HDAC8 Direct 1
vorinostat, therapeutic conventional surgery, bortezomib HDAC8 Direct 1
belinostat HDAC8 Direct yes 0
panobinostat HDAC8 Direct yes 0
panobinostat lactate HDAC8 Direct yes 0
romideps HDAC8 Direct yes 0
durvalumab, tazemetostat EZH2 SSL via EZH2 1
tazemetostat EZH2 SSL via EZH2 yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.